- Home
- HNRG vs VALN Comparison
HNRG vs VALN Comparison
Compare HNRG & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- VALN
- Stock Information
- Founded
- HNRG 1949
- VALN 2012
- Country
- HNRG United States
- VALN France
- Employees
- HNRG N/A
- VALN N/A
- Industry
- HNRG Coal Mining
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HNRG Energy
- VALN Health Care
- Exchange
- HNRG Nasdaq
- VALN Nasdaq
- Market Cap
- HNRG 632.2M
- VALN 542.5M
- IPO Year
- HNRG N/A
- VALN 2021
- Fundamental
- Price
- HNRG $15.82
- VALN $5.82
- Analyst Decision
- HNRG Strong Buy
- VALN Strong Buy
- Analyst Count
- HNRG 3
- VALN 3
- Target Price
- HNRG $18.33
- VALN $15.33
- AVG Volume (30 Days)
- HNRG 702.8K
- VALN 11.5K
- Earning Date
- HNRG 08-05-2025
- VALN 08-12-2025
- Dividend Yield
- HNRG N/A
- VALN N/A
- EPS Growth
- HNRG N/A
- VALN N/A
- EPS
- HNRG N/A
- VALN N/A
- Revenue
- HNRG $410,607,000.00
- VALN $201,099,222.00
- Revenue This Year
- HNRG N/A
- VALN $18.74
- Revenue Next Year
- HNRG $9.86
- VALN $29.26
- P/E Ratio
- HNRG N/A
- VALN N/A
- Revenue Growth
- HNRG N/A
- VALN 21.64
- 52 Week Low
- HNRG $4.86
- VALN $3.62
- 52 Week High
- HNRG $19.71
- VALN $8.66
- Technical
- Relative Strength Index (RSI)
- HNRG 49.02
- VALN 44.69
- Support Level
- HNRG $14.42
- VALN $5.57
- Resistance Level
- HNRG $16.10
- VALN $6.08
- Average True Range (ATR)
- HNRG 0.68
- VALN 0.27
- MACD
- HNRG -0.04
- VALN 0.01
- Stochastic Oscillator
- HNRG 61.51
- VALN 40.27
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.